OBJECTIVES: To evaluate the utility of Adelphi Disease Specific Programmes (DSPs) to capture physician-reported payer access controls and the impact of the Institute for Clinical and Economic Review (ICER), using a published 2018 evidence report on perceived access to treatments for patients in the United States (US). METHODS: Retrospective analysis of the 2017 (n=146) and 2018 (n=80) datasets from an Adelphi DSP in a specialty category with new FDA approvals in 2016; cross-sectional surveys of prescribers in the US were assessed. Each prescriber completed a survey, stating their perception of access controls present for selected treatments. Fisher’s exact tests were used to compare between DSP datasets to determine the change in controls and formulary inclusion before and after ICER’s report. Further analysis was based on estimated product net price classification from the ICER value-based price benchmark. RESULTS: There were several directional changes in perceived access controls between the 2017 and 2018 DSP waves. The newer agents in the category exhibited the greatest change: 13.9% increase in prescribers perceiving restricted or non-availability of Product A (p=0.087), 13.6% for Product B (p=0.088) and 6.7% for Product C (p=0.4163). CONCLUSIONS: The results demonstrate that the Adelphi DSP is a robust tool for observing changes in payer category access management between cross-sectional datasets, and capturing the influence of ICER publications in a competitive category. The relationship between the ICER report and the perception of access controls is likely confounded, due to the diversity of insurance coverage observed by specialist physicians in practice and a perception bias towards more restrictive coverage. Additional work will explore the impact of access controls on prescribing behaviors as a secondary outcome of ICER reviews and the nature of changing prescribing patterns as a function of insurance coverage type and utilization management tools.